From Untouchable to Editable: How 21st-Century Gene Editing Breakthroughs Clash with Systemic Barriers
Flora Peyvandi, former President of ISTH, recently shared an encourgaing post on gene editing on X:
”Precision gene editing progresses, despite challenges: They may be the products of tomorrow, but today’s health systems do not easily support their price-tags and complex administration requirements.”
Read the full article here.
Genetic Disorders — The Untouchables, or Are They?
As precision gene-editing technologies—such as CRISPR, base editing, and prime editing—continue to advance, they hold transformative potential for treating genetic diseases once considered unmanageable.
From rare blood disorders to inherited blindness, these therapies represent a new frontier in medicine.
However, despite the scientific breakthroughs, real-world implementation remains a challenge.
High development costs, complex delivery methods, and the need for specialized infrastructure have created significant barriers for health systems worldwide.
Closing this gap will be essential for ensuring equitable access to the future of genomic medicine.
Learn more on new advancements in the field of medicine from Hemostasis Today.
-
Sep 24, 2026, 12:15Cedric Hermans: RPTH Illustrated Review on Von Willebrand Disease
-
Sep 24, 2026, 11:48Factor XII Inhibition and the Future of Contact Pathway Targeting
-
Sep 24, 2026, 08:55Andres Gudino: Clot Characterization Through Hounsfield Units in Ischemic Stroke
-
Sep 24, 2026, 06:52Gina Sado: Screening-Detected Atrial Fibrillation Carries High Risk of Heart Failure
-
Sep 24, 2026, 06:33Benjamin Vipler: Optimal Oral Anticoagulation Choice in Atrial Fibrillation and Advanced CKD
-
Sep 24, 2026, 06:08Christopher Salerno: AI-Powered At-Home Anemia Screening Advances Telehealth Access
-
Sep 24, 2026, 05:38Aya Qattan: When a Normal CBC Does Not Mean Normal Iron Status
-
Sep 24, 2026, 05:11Mastering Warm Autoimmune Hemolytic Anemia Diagnosis and Practice – ASH Education
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B